Two pivotal Phase 3 trials of Haduvio are expected to launch this year and, if positive, may support applications seeking its ...

Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics ...

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic coughFirst pivotal ...

Chronic cough in pulmonary fibrosis affects quality of life and correlates with mortality, yet objective measurement remains challenging. A wearable device combined with machine learning may offer a ...

While one of the two late-stage trials will be initiated in the second quarter, the second will be kickstarted in the second half of this year, the company said. ・The company also said that it has ...

Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo-adjusted ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving nintedanib vs. placebo had smaller changes in questionnaire scores signaling symptom ...

Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (TRVI) (NASDAQ: TRVI), a clinical-stage biopharmaceutical company ...

The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Dec. 12, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.

Clinical worsening also occurred less frequently with treprostinil ...

Chronic cough affects some 80% of patients with idiopathic pulmonary fibrosis (IPF) and most patients consider it to be one of the most distressing IPF symptoms. In an early phase trial, the ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Swigris: Before we ...